EGFRvIII-targeted alpha therapy (Fusion Pharmaceuticals/National Research Council of Canada)

N/A

Report date: 2025/06/11 10:44:59

Base Information

Drug NameEGFRvIII-targeted alpha therapy (Fusion Pharmaceuticals/National Research Council of Canada)
Drug Alias NameEGFRvIII-targeted [225]Ac-conjugate (Fusion Pharmaceuticals/National Research Council of Canada)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4] 
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational Research Council Canada
China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals IncNational Research Council Canada
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A